😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Nestle India’s net profit up 27 pc in Q4; to form a JV with Dr Reddy’s Laboratories

Published 25-04-2024, 09:21 pm
© Reuters.  Nestle India’s net profit up 27 pc in Q4; to form a JV with Dr Reddy’s Laboratories

New Delhi, April 25 (IANS) The board of directors of Nestle (NS:NEST) India has approved the execution of a definitive agreement to form a joint venture with Dr. Reddy’s Laboratories for nutritional health solutions, as the fast-moving consumer goods (FMCG) company on Thursday reported a net profit of Rs 934.17 crore for the fourth quarter (Q4) of FY24.Dr Reddy’s will hold 51 per cent while Nestle India will hold 49 per cent stake in the JV with proportionate shareholder rights to voting, dividend distribution, and other economic rights, Nestle India said in a statement.

Nestle India will have a call option to increase its shareholding up to 60 per cent after six years at Fair Market Value. Dr Reddy’s will continue to hold at least 40 per cent of the shareholding after the company exercises its call option, Nestle India said.

The joint venture is expected to become operational in the second quarter of the 2024-25 fiscal, subject to customary closing conditions.

Meanwhile, the total income for Nestle India went up 8.84 per cent to Rs 5,294.34 crore in Q4, in comparison to Rs 4,864.22 crore reported during the same period last fiscal.

"We have witnessed a strong growth momentum across our product portfolio led by a combination of pricing and mix," said Suresh Narayanan, Chairman and Managing Director, Nestle India.



Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.